Recent

% | $
Quotes you view appear here for quick access.

Eli Lilly and Company Message Board

  • NewsTraders NewsTraders Sep 21, 1998 2:53 PM Flag

    Eli Lilly terminates migraine prophylaxi

    (NewsTraders) -- Synaptic Pharmaceutical Corp.
    (SNAP) disclosed in a Form 8-K filing that Eli Lilly
    decided to terminate a drug discovery program with
    Synaptic focused on the identification and development of
    serotonin 2B antagonists for the prophylactic treatment of
    migraine.

    Lilly had previously determined, based upon competing
    priorities, to discontinue development of the compound, which
    was undergoing late preclinical testing, and to seek
    a licensee or development partner for the
    compound.

    As a result of the most-recent decision, Lilly will
    no longer seek a licensee or development partner for
    the compound.

    Synaptic had announced on
    September 3 that the migraine compound which the program
    centered on would advance into Phase III clinical trials.

 
LLY
71.32-1.33(-1.83%)1:41 PMEDT